Human complement factor H is a novel diagnostic marker for lung adenocarcinoma

International Journal of Oncology

Volumn 39, Issue 1, 2011, Pages 161-168

  Cui, Tiantian ^a   Chen, Yuan ^a   Knösel, Thomas ^a   Yang, Linlin ^a   Zöller, Kristin ^a   Galler, Kerstin ^a   Berndt, Alexander ^a   Mihlan, Michael ^b   Zipfel, Peter F ^b   Petersen, Iver ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

Author keywords

Adenocarcinoma; Complement factor H; Diagnostic marker; Lung cancer; Prognosis

Indexed keywords

COMPLEMENT FACTOR H; MESSENGER RNA; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CELL MEMBRANE; CYTOPLASM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; WESTERN BLOTTING;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMPLEMENT FACTOR H; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROTEIN BINDING; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79956027743     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1010     Document Type: Article

References (28)

1. Gazdar AF, Shigematsu H, Herz J and Minna JD: Mutations and addiction to EGFR: the Achilles heal of lung cancers? Trends Mol Med 10: 481-486, 2004.
2. Copin MC, Buisine MP, Devisme L, et al: Normal respiratory mucosa, precursor lesions and lung carcinomas: differential expression of human mucin genes. Front Biosci 6: 1264-1275, 2001.
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin 58: 71-96, 2008.
4. Kargi A, Gurel D and Tuna B: The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochern Mol Morphol 15: 415-420, 2007.
5. Varsano S, Rashkovsky L, Shapiro H, Ophir D and Mark-Bentankur T: Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 113: 173-182, 1998. (Pubitemid 28352834)
6. Wilczek E, Rzepko R, Nowis D, et al: The possible role of factor H in colon cancer resistance to complement attack. Int J Cancer 122: 2030-2037, 2008. (Pubitemid 351441192)
7. Harboe M and Mollnes TE: The alternative complement pathway revisited. J Cell Mol Med 12: 1074-1084, 2008.
8. Zipfel PF and Skerka C: FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function. Immunol Today 20: 135-140, 1999.
9. Gasque P, Thomas A, Fontaine M and Morgan BP: Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J Neuroimmunol 66: 29-40, 1996.
10. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF and Meri S: Exceptional resistance of human H2 glioblastoma cells to complement mediated killing by expression and utilization of factor H and factor H-like proteinl. J Immunol 164: 6075-6081, 2000. (Pubitemid 30389858)
11. Junnikkala S, Hakulinen J, Jarva H, et al: Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumor cells. Br J Cancer 87: 1119-1127, 2002. (Pubitemid 35418107)
12. Ajona D, Castaño Z, Garayoa M, et al: Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 64: 6310-6318, 2004. (Pubitemid 39129436)
13. Kinders R, Jones T, Root R, et al: Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 4: 2511-2520, 1998. (Pubitemid 28477919)
14. Berndt A, Borsi L, Hyckel P and Kosmehl H: Fibrillary co-deposition of laminin-5 and large unspliced tenascin-C in the invasive front of oral squamous cell carcinoma in vivo and in vitro. J Cancer Res Clin Oncol 127: 286-292, 2001.
15. Knösel T, Yu Y, Stein U, et al: Overexpression of cyclooxygenase-2 correlates with chromosomal gain at the cyclooxygenase-2 locus and decreased patient survival in advanced colorectal carcinomas. Dis Colon Rectum 47: 70-77, 2004. (Pubitemid 38040248)
16. Friese MA, Hellwage J, Jokiranta TS, et al: Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin Exp Immunol 121: 406-415, 2000. (Pubitemid 30659783)
17. Whaley K and Ruddy S: Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science 193: 1011-1013, 1976.
18. Harrison RA and Lachmann PJ: The physiological breakdown of the third component of human complement. Mol Immunol 17: 9-20, 1980. (Pubitemid 10211810)
19. Fearon DT and Austen KF: Activation of the alternative complement pathway due to resistance of zymosan-bound. Proc Natl Acad Sci USA 74: 1683-1687, 1977.
20. Cheng ZZ, Corey MJ, Pärepalo M, et al: Complement factor H as a marker for detection of bladder cancer. Clin Chem 51: 856-863, 2005. (Pubitemid 40577922)
21. Schlaf G, Beisel N, Pollok-Kopp B, Schieferdecker H, Demberg T and Götze O: Constitutive expression and regulation of rat complement factor H in primary cultures of hepatocytes, Kupffer cells, and two hepatoma cell lines. Lab Invest 82: 183-192, 2002. (Pubitemid 34160455)
22. Ajona D, Hsu YF, Corrales L, Montuenga LM and Pio R: Downregulation of Human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178: 5991-5998, 2007. (Pubitemid 46674397)
23. Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M and Sánchez-Corral P: The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 41: 355-367, 2004.
24. Sim E, Wood AB, Hsiung LM and Sim RB: Pattern of degradation of human complement fragment, C3b. FEBS Lett 132: 55-60, 1981. (Pubitemid 12248553)
25. Gasque P, Julen N, Ischenko AM, et al: Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 149: 1381-1387, 1992.
26. Leffler J, Herbert AP, Norström E, et al: Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. J Biol Chem 285: 3766-3776, 2010.
27. Mihlan M, Stippa S, Józsi M and Zipfel PF: Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ 16: 1630-1640, 2009.
28. Trauw LA, Bengtsson AA, Gelderman KA, Dahlbäck B, Sturfelt G and Blom AM: C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem 282: 28540-28548, 2007. (Pubitemid 47606049)